2025 PLENARY DEEP DIVE

Panel Discussion: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
Moderator:
Daniel ChenDaniel Chen, MD, PhD, Founder & CEO, Synthetic Design Lab


Panelists:
Paul J. CarterPaul J. Carter, PhD, Genentech Fellow, Antibody Engineering, Genentech
G. Jonah RaineyG. Jonah Rainey, PhD, Associate Vice President, Eli Lilly and Company
Janine SchuurmanJanine Schuurman, PhD, Biotech Consultant, Lust for Life Science B.V.


2025 Track Keynotes

Antibody and Albumin-Based Designs with Tailored Effector Functions and PK Properties
Jan Terje Andersen, PhD, Professor, Department of Pharmacology, University of Oslo; Research Group Leader, Department of Immunology, Oslo University Hospital


AI for Antibody Design - Going Beyond the Static
Charlotte M. Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Executive Chair, Engineering and Physical Sciences Research Council (EPSRC)


Development of a First-in-Class, ADCC-Enhanced Bispecific NK Engager that Simultaneously Blocks EGFR Receptor-Ligand Interactions on Tumour Cells and Engages a Novel NK-Activating Receptor
Hemanta Baruah, PhD, Founder & CEO, Aakha Biologics


Unlocking MYC: Clinical Insights and Synergistic Combinations with a Novel Therapeutic Modality
Marie-Eve Beaulieu, PhD, Co-Founder & CSO, Drug Development, Peptomyc SL


Proximity-Driven Site-Specific Cyclisation of Phage-Displayed Peptides
Gonçalo Bernardes, PhD, Professor, Chemistry, University of Cambridge


Safety of Bispecifics, ADCs, and Combination Therapies
Rakesh Dixit, PhD, DABT, CEO & President, Bionavigen Oncology, LLC and CSO, TMAB Therapeutics, Regio Biosciences


Innovating T Cell Engager Therapy
Mark Cobbold, PhD, Vice President, Oncology Early Discovery, AstraZeneca Pharmaceuticals


Recent Advances in Multispecific Antibodies in Oncology and Beyond
Nathan D. Trinklein, PhD, Co-Founder and President, Rondo Therapeutics


Multispecific Antibodies and Avidity Engineering
Paul Parren, PhD, CSO, Gyes; Professor, Molecular Immunology, Leiden University Medical Center


Type 2 Immunity May Hold Key to Long-Term Cancer Remission
Li Tang, PhD, Associate Professor, Institute of Bioengineering (IBI) & Institute of Materials Science & Engineering (IMX), École Polytechnique Fédérale de Lausanne (EPFL)


HLA-Agnostic T Cell Receptor Recognition of Cancer
Andrew Sewell, PhD, Distinguished Research Professor & Wellcome Trust Senior Investigator, Division of Infection and Immunity, Cardiff University School of Medicine


iNKT Cells in CAR-Based Cancer Immunotherapy
Anastasios Karadimitris, PhD, MRCP, FRCPath Langmuir Chair in Haematology and Consultant Haematologist Co-Director, Centre for Haematology Director, Hugh and Josseline Langmuir Centre for Myeloma Research Centre for Haematology, Department of Immunology and Inflammation, Imperial College London Department of Haematology, Hammersmith Hospital Imperial College Healthcare NHS Trust


Delivering the Breakthrough with CAR T in Solid Tumours
Michael Hudecek, MD, Professor, Cellular Immunotherapy of Malignant Diseases, University of Wuerzburg


Reprogramming the Immune System by Multimodal Biological Immunotherapy for the Treatment of Solid Tumours
Paul Peter Tak, MD, PhD, FMedSci, President & CEO, Candel Therapeutics


AI-Driven Optimisation of Antibody Properties: Opportunities and Challenges
Andreas Evers, PhD, Associate Scientific Director, Antibody Discovery & Protein Engineering, Global Research & Development Discovery Technology, Merck Healthcare KGaA


Automated Sample Fractionation and Non-Reduced Multi-Enzyme Digestion Coupled with Nanoflow LC-MS/MS for Comprehensive Characterisation of Antibody-Drug Conjugates
Dan Bach Kristensen, PhD, Scientific Director, Symphogen


Proteins on the Rack—Mechanism of Protein Aggregation at Interfaces
Wolfgang Friess, PhD, Professor & Chair, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen


AIR Data to Predict Recombinant Protein Expression
Lovisa Holmberg Schiavone, PhD, Director, Protein Sciences, Structure & Biophysics, Discovery Sciences, R&D, AstraZeneca


Baculovirus Expression Vector System: Old Dog, New Tricks
Imre Berger, PhD, Professor of Chemistry and Biochemistry, Max Planck Centre Director, University of Bristol


Streamlining Gene Expression Workflows: The Use of Baculovirus-Mediated Gene Expression in Mammalian Cells for Recombinant Protein Production
Kim Remans, PhD, Head, Protein Expression & Purification Core Facility, EMBL Heidelberg


Exploring Log-Likelihood Scores for Ranking Antibody Sequence Designs
Talip Ucar, Senior Director, AI Research, AstraZeneca


SOT109: A CDH17 Targeting ADC with Best-in-Class Potential Activity for the Treatment of CRC and Other GI Cancers
Martin Steegmaier, PhD, CSO, SOTIO Biotech a.s.


* As of 19 June. Please see individual agenda pages for most up-to-date agenda.